Marks and Spencer Group Secures liquidity for the likely duration of the COVID crisis

Marks & Spencer Group

Marks & Spencer Group plc (LON:MKS) has now completed steps to secure liquidity for the likely duration of the COVID crisis and to underpin the recovery strategy and accelerated transformation in 2021. 

We are planning for the Clothing & Home business to be severely constrained during lockdown and highly uncertain trading conditions in a prolonged exit period. In the absence of a clear basis for forecasting, our scenario planning and stress tests are based on materially subdued trading for the balance of 2020 in Clothing & Home. M&S benefits from having a strong food business and the transition to Ocado supply is on track to proceed in September to form a multi-channel food operation. However, Food trading has been adversely affected by lockdown due to the closure of cafes and slowdown in travel and some city centre locations.

We have therefore taken steps to maximise liquidity for the likely duration of the crisis and recovery period beyond. 

– Formal agreement has been reached with the lending syndicate of banks providing the £1.1bn revolving credit facility to substantially relax or remove covenant conditions for the tests arising in September 2020, March 2021, and September 2021.

 – Marks & Spencer Group has been confirmed as an eligible issuer under the UK Government’s Covid Corporate Financing Facility (CCFF), providing significant further liquidity headroom.

 – The agreement with the banks combined with other measures we have taken means that under our base planning scenarios and even more adverse assumptions, the business would have significant undrawn credit available for the 18 months ahead.

 – As part of the planning for these measures and in order to provide for the uncertain outlook the board does not at this stage anticipate paying a dividend for the 2020/21 financial year, generating a cash saving of c.£210m.

We are scheduled to report preliminary full year results on 20 May and will at that stage provide a further update on the very significant measures being taken to reduce costs and protect cash flow during the crisis period. 

The crisis has created a very different way of working and rapid learning for the business at all levels. At the time of the results presentation we will also outline measures being taken to accelerate the transformation programme and change ways of working permanently under our “never the same again” programme currently being prepared for implementation.

Share on:

Latest Company News

Elementis raises 2026 profit guidance to $133m-$135m as revenue grows 7%

Elementis expects 2026 adjusted operating profit of $133 million to $135 million after nine-month revenue rose 7% to $479 million. The specialty chemicals group reported growth in Personal Care and Asia, alongside improved performance in the Americas.

Unilever Q3 sales grow 5.2% as FY volume growth forecast improves

Unilever reported third-quarter underlying sales growth of 5.2%, with turnover rising 6.7% to €13.3 billion. The company now expects at least 3% volume growth in 2026, following strong performance across Home Care, Personal Care and Beauty & Wellbeing.

Intertek Q3 revenue rises 7% as company maintains 2026 forecast

Intertek Group reported third-quarter revenue growth of 7% at constant currency, taking year-to-date revenue to £2.7 billion. The company expects mid-single-digit like-for-like revenue growth in 2026, alongside higher margins, earnings growth and strong free cash flow.

Oriole Resources applies for exploitation licence at Cameroon marble project

Oriole Resources has applied for an exploitation licence for its Wapouzé marble project in Cameroon, which hosts an estimated 32.2 million tonnes of marble. The company is assessing plans for annual production of 500,000 tonnes over a potential 24-year mine life and is in discussions with prospective industry partners.

Hunting cuts 2026 EBITDA forecast to $128m-$133m on Middle East disruption

Hunting PLC has lowered its 2026 EBITDA forecast to $128 million-$133 million following disruption in the Middle East, weaker short-term trading and supply chain delays. The group reported year-to-date EBITDA of approximately $89 million and said its next trading update is scheduled for 19 January 2027.

GSK reports 5% Q3 sales growth and reaffirms 2026 guidance

GSK reported third-quarter sales of £8.9 billion, up 5% at constant exchange rates, driven by 15% growth in Specialty Medicines. The pharmaceutical group maintained its 2026 guidance, expecting turnover growth of 3% to 5% and core operating profit growth of 7% to 9%.

    Search